PRESTIGE CONSMR (PBH)
(Delayed Data from NYSE)
$73.03 USD
-0.89 (-1.20%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $73.01 -0.02 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.03 USD
-0.89 (-1.20%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $73.01 -0.02 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum B VGM
Zacks News
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
What Makes Prestige Consumer Healthcare (PBH) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
PetIQ, Inc. (PETQ) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
PetIQ (PETQ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PBH Stock Might Get a Boost From Focused Brand-Building Efforts
by Zacks Equity Research
Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Here's Why 'Trend' Investors Would Love Betting on Prestige Consumer Healthcare (PBH)
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Prestige Consumer's (PBH) Q1 Earnings Beat, Margins Shrink
by Zacks Equity Research
Prestige Consumer (PBH) first-quarter sales bear the brunt of the ongoing supply chain challenges in the Clear Eyes business.
Prestige Consumer Healthcare (PBH) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Prestige Consumer Healthcare (PBH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 4.65% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Tops Q2 Earnings Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 42.86% and 12.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 133.33% and 1.86%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Prestige Consumer Healthcare (PBH) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Prestige Consumer Healthcare (PBH) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 10.64% and 1.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AHCO or PBH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. PBH: Which Stock Is the Better Value Option?
Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls
by Zacks Equity Research
Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.
Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Prestige Consumer Healthcare (PBH) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of -10.53% and 3.46%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
2 Intriguing Medical Stocks to Buy for Steady Growth as Earnings Approach
by Shaun Pruitt
Among the medical sector, Alcon (ALC) and Prestige Consumer Healthcare (PBH) are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 26.92% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Prestige Consumer Healthcare (PBH) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Will Cresco Labs Inc. (CRLBF) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cresco Labs Inc. (CRLBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IM Cannabis Corp. (IMCC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
IM Cannabis (IMCC) delivered earnings and revenue surprises of 0% and 14.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PBH vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?